Sanuwave Health (SNWV)
(Delayed Data from OTC)
$0.03 USD
+0.01 (40.00%)
Updated Sep 19, 2024 03:57 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for Sanuwave Health Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 20 | 17 | 13 | 4 | 1 |
Cost Of Goods | 6 | 4 | 5 | 1 | 1 |
Gross Profit | 14 | 12 | 8 | 3 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 15 | 21 | 22 | 28 | 9 |
Income After Depreciation & Amortization | -1 | -9 | -14 | -25 | -9 |
Non-Operating Income | -10 | 13 | -6 | -3 | 0 |
Interest Expense | 16 | 14 | 7 | 3 | 2 |
Pretax Income | -26 | -10 | -27 | -31 | -10 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -26 | -10 | -27 | -31 | -10 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -26 | -10 | -27 | -31 | -10 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 7 | -3 | -10 | -24 | -9 |
Depreciation & Amortization (Cash Flow) | 8 | 6 | 4 | 2 | 0 |
Income After Depreciation & Amortization | -1 | -9 | -14 | -25 | -9 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 793.85 | 549.47 | NA | NA | 203.59 |
Diluted EPS Before Non-Recurring Items | -0.03 | -0.02 | NA | NA | -0.05 |
Diluted Net EPS (GAAP) | -0.03 | -0.02 | -0.05 | -0.08 | -0.05 |
Fiscal Year end for Sanuwave Health Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 7.16 | 5.79 | 7.00 | 4.95 | 4.68 |
Cost Of Goods | 1.92 | 1.58 | 2.16 | 1.41 | 1.20 |
Gross Profit | 5.24 | 4.20 | 4.84 | 3.54 | 3.47 |
SG&A, R&D, and Dept/Amort Expenses | 3.25 | 5.25 | 3.79 | 4.08 | 2.55 |
Income After SG&A, R&D, and Dept/Amort Expenses | 1.99 | -1.05 | 1.05 | -0.54 | 0.92 |
Non-Operating Income | 8.35 | 0.08 | 20.32 | -19.32 | -3.81 |
Interest Expense | 3.78 | 3.56 | 3.12 | 3.85 | 4.38 |
Pretax Income | 6.56 | -4.53 | 18.24 | -23.70 | -7.26 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | 6.56 | -4.53 | 18.24 | -23.70 | -7.26 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | 6.56 | -4.53 | 18.24 | -23.70 | -7.26 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 1,182.60 | 1,162.25 | 607.83 | 892.96 | 582.33 |
Diluted EPS Before Non-Recurring Items | 0.01 | 0.00 | 0.03 | -0.01 | -0.01 |
Diluted Net EPS (GAAP) | 0.00 | 0.00 | 0.03 | -0.03 | -0.01 |